Randomised placebo-controlled trials for the induction of inflammatory bowel disease (IBD) remission involve potential harms to those receiving placebo. Whether these harms are also apparent with placebo during maintenance of remission trials in IBD is unclear. We aimed to examine the potential harms associated with receiving placebo in trials of licensed biologics and small molecules for maintenance of remission of ulcerative colitis and luminal Crohn's disease in a meta-analysis.

中文翻译：

---

在生物疗法和小分子作为炎症性肠病维持疗法的试验中，安慰剂的危害：系统评价和荟萃分析


诱导炎症性肠病 （IBD） 缓解的随机安慰剂对照试验涉及对接受安慰剂的患者的潜在危害。在 IBD 的维持缓解试验期间，安慰剂的这些危害是否也很明显尚不清楚。在一项荟萃分析中，我们旨在检查在许可生物制剂和小分子药物维持溃疡性结肠炎和管腔性克罗恩病缓解的试验中接受安慰剂相关的潜在危害。